Canaccord Genuity on Optimer Pharmaceuticals (OPTR): June Blip, But Trends Remain Strong & Doctors Are Interested

Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $22.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on expectation of steady revenue growth driven by unmet need and Dificid’s superior efficacy in Clostridium difficile-associated diarrhea (CDAD). We feel there is still unmet need given relapse rates associated with other Tx, rising incidence of CDAD, and growing severity of the disease. We think the pharmaco-economics of Dificid Tx (driven by fewer relapses requiring extended or repeated hospital stays) will drive uptake over time, despite premium pricing."

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $13.66 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Riskified Ltd. (RSKD) PT Raised to $7.50 at DA Davidson on Improving New Business Trends
• MongoDB (MDB) PT Raised at RBC Capital; 'Shares represent an attractive buying opportunity'
• Brinker Int'l (EAT) PT Raised to $275 at KeyBanc